 | David Hung, M.D. President and Chief Executive Officer, Director Dr. Hung served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. ProDuct Health, Inc was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College. Top |
|
|
|
 |
C. Patrick Machado, J.D.
Chief Business Officer, Chief Financial Officer
Mr. Machado was appointed chief business officer in December 2009, and has served as chief financial officer since 2004. From 1998 to 2001, he served as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer (2000-2001) of ProDuct Health, Inc., a privately-held medical device company. From 2001 to 2002, he served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 to 1998, Mr. Machado served as head of business development for new projects (working with Dr. Hung) and in senior business development and legal functions at Chiron Corporation. He received a J.D. cum laude from Harvard Law School and a B.A. and B.S. summa cum laude in German and economics, respectively, from Santa Clara University.
Top
|
|
|
|
 | Rohan Palekar, M.B.A.
Chief Commercial Officer Mr. Palekar joined Medivation as chief commercial officer in January 2008, following a 16-year commercial career at the Johnson & Johnson family of companies in positions of increasing seniority. From 2005 to 2008, Mr. Palekar served as vice president, sales and marketing—dermatology for Centocor, Inc., where he led the sales and marketing group for Remicade®, a multi-billion dollar anti-TNF antibody. From 2003 to 2005, Mr. Palekar was worldwide vice president, global biologics strategic marketing for Centocor/Johnson & Johnson, where he managed a portfolio of more than 10 molecules targeting a broad range of indications. Mr. Palekar also served as a member of the Johnson & Johnson Pharmaceuticals Group Marketing Excellence Steering Committee. Mr. Palekar earned a Bachelor of Commerce and a Bachelor of General Laws from the University of Bombay and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College. Top |
|
|
|
 | Lynn Seely, M.D. Chief Medical Officer Dr. Seely joined Medivation as chief medical officer in May 2005. From 2002 to 2005, she served as vice president of clinical development at Corgentech, Inc. (Anesiva, Inc.), a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on the faculty at the University of California, San Diego prior to joining industry. Top |
|
|
|
 | Michele D. Bronson, Ph.D. Vice President, Regulatory and Quality Dr. Bronson joined Medivation in September 2006 as senior director, regulatory, quality and project management and was promoted to vice president, regulatory and quality in January 2008. Prior to joining Medivation, Dr. Bronson held positions of increasing responsibility in regulatory affairs at Chiron Corporation, including director in the oncology development organization, where she was responsible for approved products and developmental therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of DOXIL for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Research, a contract research organization. She earned a Ph.D. in molecular immunology from the University of Texas Southwestern Medical School and completed a post-doctoral fellowship at the University of California, San Francisco. Top |
|
|
|
 | Sarvajit Chakravarty, Ph.D. Vice President, Medicinal Chemistry Dr. Chakravarty joined Medivation as vice president of medicinal chemistry in July 2007. He has more than 15 years of experience in medicinal chemistry, drug discovery and development in several therapeutic areas, including central nervous system disorders, inflammation and oncology. Previously, he held medicinal chemistry positions of increasing seniority at Scios, Inc., serving most recently as director of medicinal chemistry. While at Scios, which was acquired in 2003 by Johnson & Johnson, he played a significant role in the discovery and development of novel kinase inhibitors. Dr. Chakravarty is an author on more than 30 scientific publications and an inventor on 15 issued patents. He received his B.Sc. in chemistry from St. Stephen’s College, Delhi University in Delhi, India, and his Ph.D. in organic chemistry from New York University. Top |
|
|
|
| |
Vandana Date, J.D.
Vice President, Intellectual Property
Ms. Date joined Medivation in April 2007 as senior director of intellectual property, bringing 14 years of intellectual property related experience and over five years of experience as a research chemist. Prior to joining Medivation, she served as a director of intellectual property at Threshold Pharmaceuticals, Inc. and a patent attorney at ALZA/Johnson & Johnson and held various patent-related positions at Robins & Associates and Glycomed Inc. Ms. Date received her M.S. in chemistry from both Bombay University and Duke University and a J.D. from Golden Gate University School of Law.
Top
|
|
|
|
 | Mohammad Hirmand, M.D. Vice President, Clinical Development Dr. Hirmand joined Medivation as senior director, clinical development in August 2007 and was promoted to vice president, clinical development in February 2008. Before joining the Company, he was a senior director of clinical development at Nuvelo, Inc., where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Earlier in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance, Inc. Dr. Hirmand received his M.D. from Harvard Medical School. Top |
|
|
|
 | Andria Langenberg, M.D. Vice President, Clinical Development Dr. Langenberg joined Medivation in July 2008 with nearly 20 years of domestic and international clinical research and development experience, including Phase 1-3 vaccine and drug development experience at Chiron Corporation, development for serious pediatric conditions at BioMarin Pharmaceutical Inc. and dermatologic product development at Corgentech, Inc. (Anesiva, Inc.) and Neosil, Inc. Prior to joining Medivation, Dr. Langenberg served as the head of clinical development and a member of the executive management team at Neosil, Inc., a dermatology-focused private biopharmaceutical company. Dr. Langenberg is the author of numerous scientific publications in peer-reviewed journals. She graduated from the University of Nebraska Medical Center with highest distinction and Alpha Omega Alpha, and completed internal medicine and dermatology residency training at the University of California, San Francisco. She is board certified in internal medicine and dermatology and is on the faculty at the University of California, San Francisco. Top |
|
|
|
 |
Hank Mansbach, M.D.
Vice President of Medical Affairs
Dr. Mansbach joined Medivation as vice president of medical affairs in August 2009. He is a neurologist with more than 10 years of strategic and operational drug development experience across all phases of development and multiple therapeutic areas. Prior to joining Medivation, he was senior vice president and head of global drug development at Valeant Pharmaceuticals, a specialty pharmaceutical company. At Valeant, among other programs, he led the development of retigabine, a novel epilepsy therapy which successfully completed Phase 3 trials in 2008 and was subsequently licensed to GlaxoSmithKline (GSK). From 2004 to 2006, Dr. Mansbach was chief medical officer and vice president for clinical development at Cortex Pharmaceuticals, an emerging biotechnology company developing novel CNS therapeutics. Dr. Mansbach began his industry career in the U.S. medical affairs department at GlaxoWellcome supporting the commercialization of Imitrex®/Imigran® and Lamictal® before taking on leadership roles in the GSK Neurosciences clinical development organization. While at GSK he worked on programs in migraine, stroke, epilepsy, multiple sclerosis, pain and Alzheimer's disease.
Top
|
|
|
|
 | Joyce Mordenti, Ph.D. Vice President, Translational Medicine Dr. Mordenti joined Medivation in July 2007 as senior director, translational medicine and was promoted in February 2008 to vice president, translational medicine. Dr. Mordenti has more than 20 years of clinical and preclinical experience at multidisciplinary drug discovery and development organizations. Prior to joining Medivation, she was senior director of drug metabolism and pharmacokinetics for Celera Genomics (formerly Axys). Before that, she held positions of increasing seniority at Genentech, including group leader/senior scientist of experimental therapeutics in the Research Division. Earlier in her career, she served as associate director of the Clinical Drug Studies Unit at the University of California, San Francisco, School of Pharmacy. She received a Ph.D. in pharmaceutical sciences from the University of Connecticut and received training as a clinical fellow at the University of California, San Francisco School of Medicine. Top |
|
|
|
 | Andrew A. Protter, Ph.D. Vice President, Preclinical Development Dr. Protter joined Medivation in September 2006 following a 24-year career at Scios, Inc., where he served most recently as vice president, biology. At Scios, which was acquired in 2003 by Johnson & Johnson, Dr. Protter had responsibility for all preclinical development activities for Natrecor®, a recombinant protein approved by the FDA in 2001 to treat acute decompensated heart failure, and for multiple small-molecule product candidates. In recognition of his work, Dr. Protter was awarded the 2004 Johnson Medal for Natrecor research and development. Dr. Protter has published extensively in the fields of natriuretic peptides, lipid transport and intracellular kinases regulating inflammation, pain and fibrosis. He received a Ph.D. in biochemistry from the State University of New York, Stony Brook. Top |
|
|
|
| | Brian Selby Vice President, Biometrics Mr. Selby joined Medivation in October 2007 as a senior director of biometrics, bringing 20 years experience in analyzing clinical trial data in oncology, vascular disease, infectious disease, pain management and auto-immune disease indications. Prior to joining Medivation, he served as a director of statistical programming at ALZA/Johnson & Johnson, Nuvelo, Inc., Corgentech Inc. and InterMune, Inc., and he has performed various statistician and statistical programming functions for companies including Abgenix, Inc., Gilead Sciences, Genentech, Inc., Matrix Pharmaceutical and Monsanto. Mr. Selby earned his B.A. in mathematics from Washburn University and his M.S. in statistics from Kansas State University. Top |
|
|
|
 | Sue Wollowitz, Ph.D. Vice President, Chemistry and Manufacturing Dr. Wollowitz joined Medivation as vice president, chemistry and manufacturing, in December 2006. She has more than 20 years of experience in drug discovery and development. Previously, she served as president of Wollowitz Associates, a consulting business that assists small and emerging pharmaceutical companies in process scale-up, outsourcing, in-licensing and regulatory approvals. Prior to that, she held various senior positions at Cerus Corporation, including vice president of chemical technology and vice president of shared sciences, where she led the discovery and product development of novel compounds for inactivation of pathogens in blood products. Dr. Wollowitz previously worked at Dow Chemical Company. She has invented several novel antivirals, one of which is sold commercially in Europe, as well as novel pesticides and polymer additives. Dr. Wollowitz received her B.A. in chemistry from the State University of New York at Binghamton and her Ph.D. in organic chemistry from the University of Wisconsin at Madison. Top |
|
|
|
|
